Interaction between drugs and the gut microbiome
Interaction between drugs and the gut microbiome
复制标题
DOI：
10.1136/gutjnl-2019-320204
复制
发表时间：
2020-08-01
期刊：
影响因子：
24.5
通讯作者：
Fu, Jingyuan
中科院分区：
文献类型：
--
作者：
Weersma, Rinse K.;Zhernakova, Alexandra;Fu, Jingyuan
人体肠道微生物群是一个复杂的生态系统，可以调节人类宿主与环境的相互作用。肠道微生物与常用非抗生素药物之间的相互作用是复杂的和双向的：肠道微生物群的组成可以受到药物的影响，但反之亦然，肠道微生物群也可以通过酶作用改变药物的结构并改变其生物利用度、生物活性或毒性(药物微生物制剂)来影响个人对药物的反应。肠道微生物群也可以间接影响个人在癌症治疗中对免疫治疗的反应。在这篇综述中，我们讨论了微生物与药物之间的双向相互作用，描述了常用非抗生素药物引起的肠道微生物区系的变化及其潜在的临床后果，并总结了微生物组如何影响药物有效性及其在免疫治疗中的作用。了解微生物组是如何代谢药物和降低治疗有效性的，将开启调节肠道微生物组以改善治疗的可能性。
The human gut microbiome is a complex ecosystem that can mediate the interaction of the human host with their environment. The interaction between gut microbes and commonly used non-antibiotic drugs is complex and bidirectional: gut microbiome composition can be influenced by drugs, but, vice versa, the gut microbiome can also influence an individual's response to a drug by enzymatically transforming the drug's structure and altering its bioavailability, bioactivity or toxicity (pharmacomicrobiomics). The gut microbiome can also indirectly impact an individual's response to immunotherapy in cancer treatment. In this review we discuss the bidirectional interactions between microbes and drugs, describe the changes in gut microbiota induced by commonly used non-antibiotic drugs, and their potential clinical consequences and summarise how the microbiome impacts drug effectiveness and its role in immunotherapy. Understanding how the microbiome metabolises drugs and reduces treatment efficacy will unlock the possibility of modulating the gut microbiome to improve treatment.